Candel Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Candel Therapeutics is Paul-Peter Tak, benoemd in Sep2020, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.48M, bestaande uit 45.1% salaris en 54.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.48% van de aandelen van het bedrijf, ter waarde $ 753.25K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 6 jaar.

Belangrijke informatie

Paul-Peter Tak

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris	45.1%
Dienstverband CEO	4.2yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	2.7yrs
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Jul 01

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Apr 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Sep 15

Candel Therapeutics appoints CFO, chief medical officer

Sep 07

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Oct 21

Analyse CEO-vergoeding

Hoe is Paul-Peter Tak's beloning veranderd ten opzichte van Candel Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$52m
Jun 30 2024	n/a	n/a	-US$50m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$1m	US$670k	-US$38m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$2m	US$670k	-US$19m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$957k	US$545k	-US$36m
Sep 30 2021	n/a	n/a	-US$48m
Jun 30 2021	n/a	n/a	-US$35m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$3m	US$135k	-US$18m

Compensatie versus markt: De totale vergoeding ($USD 1.48M ) Paul-Peter } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Paul-Peter is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paul-Peter Tak (63 yo)

4.2yrs

Tenure

US$1,484,759

Compensatie

Dr. Paul-Peter Tak, M.D. PH.D. FMEDSCI, has been Member of Advisory Board at SecondWave Systems, Inc. from March 2024. He serves as President & Chief Executive Officer at Candel Therapeutics, Inc. since Se...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul-Peter Tak	President	4.2yrs	US$1.48m	0.48% $ 753.2k
Francesca Barone	Chief Scientific Officer	2.8yrs	US$706.88k	0.18% $ 281.3k
Charles Schoch	Interim CFO	1.7yrs	geen gegevens	0.070% $ 110.7k
Seshu Tyagarajan	Chief Technical & Development Officer	2.6yrs	US$916.02k	0.18% $ 275.6k
Ileen Winick	Chief People Officer	no data	geen gegevens	geen gegevens
Susan Stewart	Chief Regulatory Officer	4.1yrs	geen gegevens	geen gegevens
William Nichols	Chief Medical Officer	2.2yrs	geen gegevens	0.13% $ 197.6k

2.7yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CADL wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul-Peter Tak	President	4.2yrs	US$1.48m	0.48% $ 753.2k
Joseph Papa	Independent Director	2.3yrs	US$58.19k	0.12% $ 184.1k
Edward Benz	Member of Research Advisory Board & Director	7.2yrs	US$56.19k	0% $ 0
Paul Manning	Independent Chairman	6yrs	US$83.19k	7.15% $ 11.2m
Scott Eggener	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Adam Kibel	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
E. Chiocca	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Christopher Martell	Independent Director	6yrs	US$67.19k	2.03% $ 3.2m
Charu Aggarwal	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Steven Albelda	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Mark Bloomston	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Tri Le	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CADL wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

Candel Therapeutics Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Candel Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Candel Therapeutics, Inc. Announces Chief Financial Officer Changes

Candel Therapeutics, Inc. Appoints Nicoletta Loggia to the Board of Directors

Candel Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Independent Director recently bought US$73k worth of stock

Candel Therapeutics Announces Jason A. Amello as Chief Financial Officer, Effective September 21, 2022

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Candel Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

New major risk - Share price stability

Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Candel Therapeutics, Inc. Announces Chief Financial Officer Changes

Candel Therapeutics, Inc. Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.30 loss in 3Q 2022)

New major risk - Share price stability

Candel Therapeutics, Inc. Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Candel Therapeutics, Inc. Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

Price target increased by 8.6% to US$9.50

First half 2023 earnings released: US$0.64 loss per share (vs US$0.17 loss in 1H 2022)

New major risk - Financial position

New major risk - Share price stability

Candel Therapeutics, Inc. Appoints Nicoletta Loggia to the Board of Directors

Candel Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of Can-3110 in Recurrent High-Grade Glioma At the American Society of Gene & Cell Therapy 26Th Annual Meeting

Price target decreased by 17% to US$7.25

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.03 loss in 1Q 2022)

Full year 2022 earnings released: US$0.65 loss per share (vs US$1.91 loss in FY 2021)

Independent Director recently bought US$73k worth of stock

Consensus forecasts updated

Price target decreased to US$11.60

Candel Therapeutics, Inc. R&D Day Presentations Spotlight Its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

Candel Therapeutics Announces Oral Presentation of Updated Data from Its Phase 1 Clinical Trial of Can-3110 in 41 Patients with Recurrent High-Grade Glioma At the Society for Neuro-Oncology 27Th Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics Announces Jason A. Amello as Chief Financial Officer, Effective September 21, 2022

Candel Therapeutics appoints CFO, chief medical officer

Candel Therapeutics, Inc., Annual General Meeting, Oct 13, 2022

Consensus forecasts updated

Consensus forecasts updated

Less than half of directors are independent

First half 2022 earnings released

Candel Therapeutics, Inc. Announces Executive Changes

Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index

Candel Therapeutics, Inc. Releases Initial Data on CAN-2409 in A Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Candel Therapeutics, Inc Expects to Present Initial Data from an Ongoing Phase 2 Clinical Trial of CAN-2409

Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer

Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer

Candel Therapeutics, Inc. Appoints Dr. Francesca Barone as Chief Scientific Officer

Candel Therapeutics, Inc. Removes Estuardo Aguilar-Cordova and Laura Aguilar from the Board

Candel Therapeutics, Inc. and Partnership for Accelerating Cancer Therapies to Collaborate on Lung Cancer Trial for CAN-2409

Third quarter 2021 earnings released: US$0.69 loss per share

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Chairman recently bought US$411k worth of stock

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden